Bilateral Posterior Uveitis and Retinal Detachment During Immunotherapy: A Case Report and Literature Review

被引：7

作者：

Peng, Ling ^{[1
,2
]}

Mao, Qi-Qi ^{[3
]}

Jiang, Bo ^{[4
]}

Zhang, Jin ^{[5
]}

Zhao, Yi-Lei ^{[6
]}

Teng, Xiao-Dong ^{[7
]}

Yang, Jin-Song ^{[1
]}

Xia, Yang ^{[8
]}

Chen, Shi-Qing ^{[9
]}

Stebbing, Justin ^{[10
]}

Jiang, Hai ^{[3
]}

机构：

[1] Zhejiang Univ, Affiliated Hosp 1, Sch Med, Dept Radiotherapy, Hangzhou, Peoples R China

[2] Zhejiang Prov Peoples Hosp, Dept Resp Dis, Hangzhou, Peoples R China

[3] Zhejiang Univ, Affiliated Hosp 1, Sch Med, Dept Urol, Hangzhou, Peoples R China

[4] Zhejiang Univ, Affiliated Hosp 1, Sch Med, Dept Ophthalmol, Hangzhou, Peoples R China

[5] Renji Hosp, Dept Urol, Shanghai, Peoples R China

[6] Zhejiang Univ, Affiliated Hosp 1, Sch Med, Dept Radiol, Hangzhou, Peoples R China

[7] Zhejiang Univ, Affiliated Hosp 1, Sch Med, Dept Pathol, Hangzhou, Peoples R China

[8] Zhejiang Univ, Dept Resp & Crit Care Med, Sch Med 2, Affiliated Hosp, Hangzhou, Peoples R China

[9] 3D Med Inc, Med Dept, Shanghai, Peoples R China

[10] Imperial Coll London, Dept Surg & Canc, Div Canc, London, England

来源：

FRONTIERS IN ONCOLOGY | 2020年 / 10卷

关键词：

retinal detachment; immune checkpoint inhibitor; pembrolizumab; immunotherapy; anti-angiogenesis; IMMUNE CHECKPOINT BLOCKADE; ADVERSE EVENTS; CANCER-IMMUNITY; CELL-CARCINOMA; MANAGEMENT; CHEMOTHERAPY; TOXICITIES; NIVOLUMAB; PEMBROLIZUMAB; DIAGNOSIS;

D O I：

10.3389/fonc.2020.549168

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Immune checkpoint inhibitors (ICIs) cause fewer toxicities than conventional chemotherapy. Although most of the immune-related adverse events (irAEs) are mild, reversible, and manageable, potentially severe and rare irAEs remain relevant. We present a 24-year-old man with advanced hereditary renal cancer who developed bilateral posterior uveitis and retinal detachment after systematic treatment of ICI and an anti-angiogenic drug. Axitinib and pembrolizumab were administered with a partial response and following the severe ocular irAE and systemic corticosteroid treatment was initiated. Our case indicates that ocular irAEs may occur rapidly. To the best of our knowledge, this is the first case of posterior uveitis and retinal detachment in hereditary renal cancer patients treated with ICI and anti-angiogenic drugs.

引用

页数：8

共 61 条

[1] Immune-related ocular toxicities in solid tumor patients treated with immune checkpoint inhibitors: a systematic review [J].

Abdel-Rahman, Omar ;

Oweira, Hani ;

Petrausch, Ulf ;

Helbling, Daniel ;

Schmidt, Jan ;

Mannhart, Meinrad ;

Mehrabi, Arianeb ;

Schoeb, Othmar ;

Giryes, Anwar .

EXPERT REVIEW OF ANTICANCER THERAPY, 2017, 17 (04) :387-394

[2] Immune-Related Adverse Events by Immune Checkpoint Inhibitors Significantly Predict Durable Efficacy Even in Responders with Advanced Non-Small Cell Lung Cancer [J].

Akamatsu, Hiroaki ;

Murakami, Eriko ;

Oyanagi, Jun ;

Shibaki, Ryota ;

Kaki, Takahiro ;

Takase, Eri ;

Tanaka, Masanori ;

Harutani, Yuhei ;

Yamagata, Nao ;

Okuda, Yuka ;

Furuta, Katsuyuki ;

Sugimoto, Takeya ;

Teraoka, Shunsuke ;

Hayata, Atsushi ;

Tokudome, Nahomi ;

Ozawa, Yuichi ;

Mori, Keita ;

Koh, Yasuhiro ;

Yamamoto, Nobuyuki .

ONCOLOGIST, 2020, 25 (04) :E679-E683

[3] Programmed death-1 (PD-1) receptor/PD-1 ligand (PD-L1) expression in fumarate hydratase-deficient renal cell carcinoma [J].

Alaghehbandan, Reza ;

Stehlik, Jan ;

Trpkov, Kiril ;

Magi-Galluzzi, Cristina ;

Mundo, Enric Condom ;

Foix, Maria Pane ;

Berney, Daniel ;

Sibony, Mathilde ;

Suster, Saul ;

Agaimy, Abbas ;

Montiel, Delia Perez ;

Pivovarcikova, Kristyna ;

Michalova, Kvetoslava ;

Daum, Ondrej ;

Ondic, Ondrej ;

Rotterova, Pavla ;

Dusek, Martin ;

Hora, Milan ;

Michal, Michal ;

Hes, Ondrej .

ANNALS OF DIAGNOSTIC PATHOLOGY, 2017, 29 :17-22

[4] Updated European Association of Urology Guidelines on Renal Cell Carcinoma: Immune Checkpoint Inhibition Is the New Backbone in First-line Treatment of Metastatic Clear-cell Renal Cell Carcinoma [J].

Albiges, Laurence ;

Powles, Tom ;

Staehlerr, Michael ;

Bensalan, Karim ;

Giles, Rachel H. ;

Hora, Milan ;

Kuczyk, Markus A. ;

Lam, Thomas B. ;

Ljungberg, Brje ;

Marconi, Lorenzo ;

Merseburger, Axel S. ;

Volpe, Alessandro ;

Abu-Ghanem, Yasmin ;

Dabestani, Saeed ;

Fernandez-Pello, Sergio ;

Hofmann, Fabian ;

Kuusk, Teele ;

Tahbaz, Rana ;

Bex, Axel .

EUROPEAN UROLOGY, 2019, 76 (02) :151-156

[5] The privileged immunity of immune privileged organs: the case of the eye [J].

Benhar, Inbal ;

London, Anat ;

Schwartz, Michal .

FRONTIERS IN IMMUNOLOGY, 2012, 3

[6] Prevalence and Clinical Patterns of Ocular Complications Associated With Anti-PD-1/PD-L1 Anticancer Immunotherapy [J].

Bitton, Karen ;

Michot, Jean-Marie ;

Barreau, Emmanuel ;

Lambotte, Olivier ;

Haigh, Oscar ;

Marabelle, Aurelien ;

Voisin, Anne-Laure ;

Mateus, Christine ;

Remond, Anne-Laure ;

Couret, Chloe ;

Champiat, Stephane ;

Labetoulle, Marc ;

Rousseau, Antoine .

AMERICAN JOURNAL OF OPHTHALMOLOGY, 2019, 202 :109-117

[7] Nivolumab versus Docetaxel in Advanced Nonsquamous Non-Small-Cell Lung Cancer [J].

Borghaei, H. ;

Paz-Ares, L. ;

Horn, L. ;

Spigel, D. R. ;

Steins, M. ;

Ready, N. E. ;

Chow, L. Q. ;

Vokes, E. E. ;

Felip, E. ;

Holgado, E. ;

Barlesi, F. ;

Kohlhaeufl, M. ;

Arrieta, O. ;

Burgio, M. A. ;

Fayette, J. ;

Lena, H. ;

Poddubskaya, E. ;

Gerber, D. E. ;

Gettinger, S. N. ;

Rudin, C. M. ;

Rizvi, N. ;

Crino, L. ;

Blumenschein, G. R. ;

Antonia, S. J. ;

Dorange, C. ;

Harbison, C. T. ;

Finckenstein, F. Graf ;

Brahmer, J. R. .

NEW ENGLAND JOURNAL OF MEDICINE, 2015, 373 (17) :1627-1639

[8] Safety profiles of anti-CTLA-4 and anti-PD-1 antibodies alone and in combination [J].

Boutros, Celine ;

Tarhini, Ahmad ;

Routier, Emilie ;

Lambotte, Olivier ;

Ladurie, Francois Leroy ;

Carbonnel, Franck ;

Izzeddine, Hassane ;

Marabelle, Aurelien ;

Champiat, Stephane ;

Berdelou, Armandine ;

Lanoy, Emilie ;

Texier, Matthieu ;

Libenciuc, Cristina ;

Eggermont, Alexander M. M. ;

Soria, Jean-Charles ;

Mateus, Christine ;

Robert, Caroline .

NATURE REVIEWS CLINICAL ONCOLOGY, 2016, 13 (08) :473-486

[9] Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: American Society of Clinical Oncology Clinical Practice Guideline [J].

Brahmer, Julie R. ;

Lacchetti, Christina ;

Schneider, Bryan J. ;

Atkins, Michael B. ;

Brassil, Kelly J. ;

Caterino, Jeffrey M. ;

Chau, Ian ;

Ernstoff, Marc S. ;

Gardner, Jennifer M. ;

Ginex, Pamela ;

Hallmeyer, Sigrun ;

Chakrabarty, Jennifer Holter ;

Leighl, Natasha B. ;

Mammen, Jennifer S. ;

McDermott, David F. ;

Naing, Aung ;

Nastoupil, Loretta J. ;

Phillips, Tanyanika ;

Porter, Laura D. ;

Puzanov, Igor ;

Reichner, Cristina A. ;

Santomasso, Bianca D. ;

Seigel, Carole ;

Spira, Alexander ;

Suarez-Almazor, Maria E. ;

Wang, Yinghong ;

Weber, Jeffrey S. ;

Wolchok, Jedd D. ;

Thompson, John A. .

JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (17) :1714-+

[10] Current issues and perspectives in PD-1 blockade cancer immunotherapy [J].

Chamoto, Kenji ;

Hatae, Ryusuke ;

Honjo, Tasuku .

INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY, 2020, 25 (05) :790-800

← 1 2 3 4 5 6 7 →